Evidence map›Paper›PMID 28317169›Full record

ArticleJournal of clinical laboratory analysis2018

Molecular characteristics of ofloxacin mono-resistant Mycobacterium tuberculosis isolates from new and previously treated tuberculosis patients.

Zhirui Wang, Tong Xie, Cheng Mu, Chunhua Wang, Hanfang Ju, Hui Zhao, Rui Sun

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Revisiting the methods for detectingAccess microbiology · 2021
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhirui WangDepartment of Microbiology, Tianjin Centers for Disease Control and Prevention, Tianjin, China.ORCID http://orcid.org/0000-0002-5860-5462
Tong XieDepartment of Microbiology, Tianjin Centers for Disease Control and Prevention, Tianjin, China.
Cheng MuTuberculosis Reference Laboratory, Tianjin Center for Tuberculosis Control, Tianjin, China.
Chunhua WangTuberculosis Reference Laboratory, Tianjin Center for Tuberculosis Control, Tianjin, China.
Hanfang JuTuberculosis Reference Laboratory, Tianjin Center for Tuberculosis Control, Tianjin, China.
Hui ZhaoTuberculosis Reference Laboratory, Tianjin Center for Tuberculosis Control, Tianjin, China.
Rui SunTuberculosis Reference Laboratory, Tianjin Center for Tuberculosis Control, Tianjin, China.
Center for Tuberculosis Control of Guangdong Province · CNTianjin Centers for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOfloxacin (OFX) resistant Mycobacterium tuberculosis (MTB) isolates have been increasingly observed and are a major concern in recent years. This study investigated the genetic mutations associated with OFX resistance among clinical OFX mono-resistant MTB isolates from new and previously treated tuberculosis patients.

methodsA total of 50 unrelated OFX mono-resistant MTB isolates were analyzed. For all isolates, the quinolone resistance determining regions of gyrA and gyrB were PCR amplified and sequenced.

resultsSingle mutations in the quinolone resistance determining regions of gyrA (positions D94A, G, N, and Y; A90V; and S91P) and gyrB (positions T539A and E540D) were observed in 62% (31/50) and 4% (2/50) of all OFX mono-resistant isolates, respectively. No differences were detected between the proportions of isolates with mutations in gyrA/gyrB from new and previously treated tuberculosis patients (P=.820).

conclusionsAlthough mutations in gyrB were rare, they were as important as mutations in gyrA in predicting OFX resistance in MTB in Tianjin, China.

Indexed as

Mycobacterium tuberculosisAdultAgedAged, 80 and overAntitubercular AgentsBacterial ProteinsDNA GyraseDrug Resistance, BacterialFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedOfloxacinTuberculosis, Multidrug-ResistantYoung AdultAntitubercular AgentsBacterial ProteinsDNA GyraseOfloxacinFluoroquinolone resistancegyrAgyrBmutationsMycobacterium tuberculosisofloxacin resistancequinolone resistance determining region

Identifiers

PMID28317169
PMCPMC6817024
OpenAlexW2597933371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.